HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (25) Citing Articles via Google Scholar Google Scholar Articles by Reich, J. M. Search for Related Content PubMed PubMed Citation Articles by Reich, J. M.

Mortality of Intrathoracic Sarcoidosis in Referral vs Population-Based Settings^*

Influence of Stage, Ethnicity, and Corticosteroid Therapy

^* From the Center for Health Research, Kaiser Permanente, Northwest Region, Portland, OR.

Correspondence to: Jerome M. Reich, MD, FCCP, 5051 SW Barnes Rd, Portland, OR 97221-1517; e-mail: Reichje{at}dnamail.com

Study objectives: To compare the sarcoidosis mortality in referral settings (RS) and population-based settings (PS), and to identify the contribution of stage, ethnicity, and corticosteroid therapy (CST) to their disparate outcomes.

Design: All observational studies identified in a MEDLINE search and bibliographic review published in the English language since 1960 dealing with the course and prognosis of sarcoidosis in large, unsorted, adult, ambulatory RS and PS providing long-term follow-up were reviewed and subjected to meta-analysis.

Measurements and results: Sarcoidosis mortality in RS (4.8%), in which 17% of patients had the most unfavorable prognosis as judged by stage (stage III), was 10-fold that reported in PS (0.5%), in which 11% of patients were identified at this stage. The magnitude of this disparity could not be accounted for solely by adverse selection, as indicated by stage or by ethnicity. Patients in RS received CST with sevenfold the frequency of PS, and its provision was highly correlated with stage-normalized mortality.

Conclusion: The prognosis of patients with intrathoracic sarcoidosis in PS is far more favorable than that obtained in RS. Sarcoidosis mortality is largely independent of ethnicity. The possibility cannot be excluded that excessive employment of CST may unfavorably influence the long-term course of the disease in some individuals.

Key Words: drug therapy • ethnology • meta-analysis • mortality • sarcoidosis

This article has been cited by other articles:

				R. L. Ferrer, S. J. Hambidge, and R. C. Maly The Essential Role of Generalists in Health Care Systems Ann Intern Med, April 19, 2005; 142(8): 691 - 699. [Abstract] [Full Text] [PDF]

				W. J. Martin II, M. C. Iannuzzi, D. B. Gail, and H. H. Peavy Future Directions in Sarcoidosis Research: Summary of an NHLBI Working Group Am. J. Respir. Crit. Care Med., September 1, 2004; 170(5): 567 - 571. [Abstract] [Full Text] [PDF]

				D. M. Skillrud, G. L. Baum, and J. Reich Sarcoidosis Cycle Chest, March 1, 2004; 125(3): 1171 - 1172. [Full Text] [PDF]

				S. Marchand-Adam, J. Marchal, M. Cohen, P. Soler, B. Gerard, Y. Castier, G. Leseche, D. Valeyre, H. Mal, M. Aubier, et al. Defect of Hepatocyte Growth Factor Secretion by Fibroblasts in Idiopathic Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., November 15, 2003; 168(10): 1156 - 1161. [Abstract] [Full Text] [PDF]

				M. A. Judson The Etiologic Agent of Sarcoidosis: What If There Isn't One? Chest, July 1, 2003; 124(1): 6 - 8. [Full Text] [PDF]

				J. M. Reich What Is Sarcoidosis? Chest, July 1, 2003; 124(1): 367 - 371. [Full Text] [PDF]

				K. W. Thomas and G. W. Hunninghake Sarcoidosis JAMA, June 25, 2003; 289(24): 3300 - 3303. [Full Text] [PDF]